忘记用户 ID? or 忘记密码?

Not a Member?


Menu 返回 Committee

Meet the Program Commitee for 2022!


  • Amy  Bertha
    Amy Bertha Executive Director, Regulatory Policy and Innovation
    Bayer, United States
  • David  Bowers, PharmD
    David Bowers, PharmD Senior Director, Operations
    PPD, United States
  • Kristina  Bowyer
    Kristina Bowyer Vice President, Patient Advocacy & Engagement
    Ionis Pharmaceuticals, Inc., United States
  • Susan  Callery-D'Amico, BSN
    Susan Callery-D'Amico, BSN Retired, Vice President, R&D Quality Assurance, AbbVie
    United States
  • Brooke  Casselberry, MS, RAC
    Brooke Casselberry, MS, RAC Vice President, Advisory and Delivery
    Epista Life Sciences, United States
  • Meghana  Chalasani, MHA
    Meghana Chalasani, MHA Associate Director for Clinical Trial Innovation, Office of New Drugs, CDER
    FDA, United States
  • Andrew  Chang, PhD
    Andrew Chang, PhD Vice President, Quality and Regulatory Compliance
    Novo Nordisk, United States
  • Wendy  Charles, PhD
    Wendy Charles, PhD Chief Ethics and Compliance Officer; Adjunct Faculty
    Equideum Health, United States
  • Ethan  Chen, MBA, MS, PMP
    Ethan Chen, MBA, MS, PMP Director, Division of Data Management Services and Solutions, OBI, OSP, CDER
    FDA, United States
  • Karla  Childers, MS
    Karla Childers, MS Head, Bioethics-Based Science and Technology Policy
    Johnson & Johnson, United States
  • Leah  Christl, PhD
    Leah Christl, PhD Exec Director, Global Biosimilars Regulatory Affairs & Regulatory & R&D Policy
    Amgen, United States
  • Freda  Cooner, PhD
    Freda Cooner, PhD Senior Director - Statistics
    Eli Lilly and Company, United States
  • Stephanie Y. Crawford, PhD, MPH, MS
    Stephanie Y. Crawford, PhD, MPH, MS Professor, Pharmacy Systems, Outcomes and Policy
    University of Illinois at Chicago, United States
  • Ebony  Dashiell-Aje, PhD
    Ebony Dashiell-Aje, PhD Executive Director and Head, Patient Centered Outcomes Science
    BioMarin, United States
  • Sameen  Desai, MBA, MS
    Sameen Desai, MBA, MS Executive Director, IT Worldwide Patient Safety
    Bristol-Myers Squibb Company, United States
  • Julie  Dietrich, MS
    Julie Dietrich, MS Vice President, Clinical Development
    GENFIT, United States
  • Hetal  Doshi, MBA
    Hetal Doshi, MBA Director, Business Operations and Strategy
    AbbVie, Inc., United States
  • Jennifer  Farmer, MS
    Jennifer Farmer, MS Chief Executive Officer
    Friedreich's Ataxia Research Alliance (FARA), United States
  • Maureen  Feeney, PharmD, MBA, RPh
    Maureen Feeney, PharmD, MBA, RPh Vice President Scientific Communications and Strategic Alliances
    Takeda, United States
  • David  Fryrear, MS
    David Fryrear, MS Executive Vice President and Head of Quality Assurance
    Astellas, United States
  • M. Scott  Furness, PhD
    M. Scott Furness, PhD Deputy Director, Office of New Drug Products, OPQ, CDER
    FDA, United States
  • Alicia  Gilsenan, PhD, MS, RPh, FISPE
    Alicia Gilsenan, PhD, MS, RPh, FISPE Vice President, Epidemiology
    RTI Health Solutions, United States
  • Renmeet  Grewal, PharmD, MS
    Renmeet Grewal, PharmD, MS Division Director, Office of Regulatory Operations (DRO-II), OND, CDER
    FDA, United States
  • Sabine  Haubenreisser, PhD, MSc
    Sabine Haubenreisser, PhD, MSc Principal Scientific Administrator, Stakeholders and Communication Division
    European Medicines Agency, Netherlands
  • Alan  Hochberg
    Alan Hochberg Principal Scientific Enablement Director, Scientific Enablement and Processes
    Genentech, A Member of the Roche Group, United States
  • Michelle  Hoiseth
    Michelle Hoiseth General Manager, Project-Based Services
    Cytel, United States
  • Kenneth  Hu, PharmD, MBA
    Kenneth Hu, PharmD, MBA Senior Manager (US Reg Lead), Global Regulatory Strategy & Policy, Oncology
    Bristol Myers Squibb, United States
  • Jeremy  Jokinen, PhD, MS
    Jeremy Jokinen, PhD, MS Vice President and Head, Safety Evidence and Sciences
    Bristol-Myers Squibb Company, United States
  • Annie  Kennedy
    Annie Kennedy Chief of Policy, Advocacy, and Patient Engagement
    EveryLife Foundation for Rare Diseases, United States
  • Cathryn C Lee, MSN
    Cathryn C Lee, MSN Director, Office of Program Operations, PDIMS, OND, CDER
    FDA, United States
  • Rebecca  Lipsitz, PhD
    Rebecca Lipsitz, PhD Senior Director, TA Regulatory Intelligence and Portfolio Policy, Late R&I RA
    AstraZeneca, United States
  • Sheila  Mahoney Jewels, MBA
    Sheila Mahoney Jewels, MBA Drug Development Multi-Functionalist
    LifeSciHub , United States
  • Ingrid  Markovic, PhD
    Ingrid Markovic, PhD Senior Science Advisor for CMC, Office of the Center Director, CBER
    FDA, United States
  • Christopher  Marrone, PharmD, RPh
    Christopher Marrone, PharmD, RPh Outcomes Liaison Advisor – National Accounts, Value, Evidence and Outcomes (VEO)
    Eli Lilly and Company, United States
  • Chris  Matheus, MBA
    Chris Matheus, MBA Chief Commercial and Networking Officer
    Global Life Sciences Alliance (GLSA), United States
  • Lindsay  McNair, MD, MPH, MS
    Lindsay McNair, MD, MPH, MS Principal Consultant
    Equipoise Consulting, United States
  • Munish  Mehra, PhD, MS, MSc
    Munish Mehra, PhD, MS, MSc Managing Director, Principal Biostatistician
    Tigermed, United States
  • Timothe  Menard, PharmD, MSc
    Timothe Menard, PharmD, MSc Global Head, Quality Excellence Digital | Bioethics Coach (Data Ethics)
    F. Hoffmann-La Roche Ltd, Switzerland
  • Alexis  Miller, JD
    Alexis Miller, JD Acting Global Lead, Global Regulatory Policy and Intelligence
    Merck & Co., Inc., United States
  • Martha  Monser
    Martha Monser Consumer Safety Officer, Office of Regulatory Operations, CBER
    FDA, United States
  • Christine  Moore, PhD
    Christine Moore, PhD Executive Director, Global External Advocacy and Standards
    Organon & Co., United States
  • Jean M. Mulinde, MD
    Jean M. Mulinde, MD Associate Director, Division of Clinical Compliance Evaluation, OSI
    FDA, United States
  • Erin  Mulrooney, MSc, PMP
    Erin Mulrooney, MSc, PMP Director, Discovery Project and Portfolio Management
    Merck Sharp & Dohme LLC , United States
  • Nobumasa  Nakashima
    Nobumasa Nakashima Health Policy Director, National Healthcare Policy Secretariat
    Cabinet Office, Japan
  • Anita  Nelsen
    Anita Nelsen Executive Vice President, Translational Medicine
    Parexel, United States
  • David O Olaleye, PhD, MSc
    David O Olaleye, PhD, MSc Senior Manager and Principal Research Statistician
    SAS Institute Inc., United States
  • Lisa  Palladino-Kim, MS
    Lisa Palladino-Kim, MS Program Director / Lecturer
    Rutgers School of Health Professions Clin Research Mgmt, United States
  • Sissi  Pham, PharmD
    Sissi Pham, PharmD Chief Executive Officer
    AESARA, United States
  • Paul  Phillips
    Paul Phillips Director, Office of Program Operations, OND, CDER
    FDA, United States
  • Margaret  Richards, PhD, MPH
    Margaret Richards, PhD, MPH Executive Director, Solutions
    Panalgo, United States
  • Earl  Seltzer, MBA
    Earl Seltzer, MBA Senior Director, Partnerships and Innovation
    CTI, United States
  • Anjali  Shah, PharmD
    Anjali Shah, PharmD Executive Director, Business Capabilities and Innovation, WWPS
    Bristol-Myers Squibb Company, United States
  • Meredith  Smith, PhD, MPA, FISPE
    Meredith Smith, PhD, MPA, FISPE Senior Director, Implementation Science Pillar Lead
    Evidera, Inc, United States
  • Evelyn  Soo, PhD, MS
    Evelyn Soo, PhD, MS Director, Bureau of Gastroenterology, Infection and Viral Diseases, HPFB
    Health Canada, Canada
  • Mat  Soukup, PhD
    Mat Soukup, PhD Deputy Director, Division of Biometrics VII, OB, OTS CDER
    FDA, United States
  • Jeffrey N. Stuart, PhD
    Jeffrey N. Stuart, PhD Associate Vice President, Global Regulatory Affairs
    Merck Sharp & Dohme LLC , United States
  • Ling  Su, PhD
    Ling Su, PhD Research Fellow
    Shenyang Pharmaceutical University, Yeehong Business School, China
  • Linda B Sullivan, MBA
    Linda B Sullivan, MBA Senior Fellow
    Tufts Center For the Study of Drug Development, United States
  • Melek  Sunay, PhD
    Melek Sunay, PhD Pharmacology and Toxicology Reviewer, DCEPT, OTAT, CBER
    FDA, United States
  • Ashley  Trieu, PharmD
    Ashley Trieu, PharmD Manager, Pharmacovigilance Scientist
    Kyowa Kirin, Inc, United States
  • Rachel  Turow, JD, MPH
    Rachel Turow, JD, MPH Managing Counsel, FDA Regulatory
    Walmart, Inc., United States
  • Pujita  Vaidya, MPH
    Pujita Vaidya, MPH North America Lead, Regulatory Science and Policy
    Sanofi, United States
  • Casey  Walker, PharmD
    Casey Walker, PharmD Pharmacist
    Jushi Holdings, Inc, United States
  • Paula  Walker, MA
    Paula Walker, MA Global Head of Risk Based Quality Management
    Roche Products Ltd., United Kingdom
  • Susan  Wang, PhD
    Susan Wang, PhD Global Head of Biostatistics and Data Sciences Inflammation
    Boehringer Ingelheim, United States
  • Nancy  Watanabe, MS, PMP
    Nancy Watanabe, MS, PMP Independent Consultant
    Independent Consultant, United States
  • Keith  Wenzel
    Keith Wenzel Volunteer
    DIA Study Endpoints Community, United States
  • Robin  Whitsell
    Robin Whitsell President
    Whitsell Innovations, Inc., United States
  • Judith  Zander, MD
    Judith Zander, MD Director, Office of Pharmacovigilance and Epidemiology, OSE, CDER
    FDA , United States
  • Martine  Zimmermann, PharmD
    Martine Zimmermann, PharmD Senior Vice President, Head of Global Regulatory Affairs
    Ipsen , France
Load More